Therapy News and Research

RSS

Chemotherapy better than chemoradiotherapy in reducing distant pancreatic cancer recurrences

Patients who received chemotherapy after surgical resection of pancreatic cancer have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy.

18 Feb 2016

Pioglitazone drug may prevent recurrent stroke and heart attacks

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes.

18 Feb 2016

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

A meta-analysis highlights the significantly increased risk of vascular occlusive events in patients with chronic myeloid leukaemia using some new-generation BCR-ABL tyrosine kinase inhibitors compared with use of imatinib.

17 Feb 2016

Allo-HSCT Non-Relapse Related Mortality Reduction Revealed

A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests.

17 Feb 2016

Mtss1 'tumour suppressor' for CML

The metastasis suppressor 1 protein acts a tumour suppressor in chronic myeloid leukaemia stem cells, reveals research published in Leukemia.

17 Feb 2016

Magnesium therapy as a relaxing Mother’s day gift

This Mother’s Day, give the most important woman in your life one of the most powerful mineral relaxation rituals – magnesium therapy.

From BetterYou Ltd 17 Feb 2016

High beam placement accuracy from new Excelitas surface mount 905nm

Excelitas Technologies® Corp., a global technology leader focused on delivering innovative, customized photonic solutions, introduced today the Surface Mount 905 nm Pulsed Semiconductor Laser (SMD Laser), offering the capability of automated pick-and-place high-volume assembly.

From Excelitas Technologies 17 Feb 2016

Studies explore causative factor of hypertension in younger, obese men and women

There's no doubt estrogen plays a big role in the differences between males and females, and now researchers want to know if it also helps explain emerging sex differences in what makes younger, obese men and women hypertensive.

17 Feb 2016

Benefit of using antibody-coated drug-eluting stents for CHD still unclear, shows report

In patients with coronary heart disease requiring a stent implantation, the benefit of treatment with antibody-coated drug-eluting stents (ABC-DES) versus drug-eluting stents without antibody coating (DES) is still unclear.

17 Feb 2016

NUS-led study reveals key player contributing to maintenance of hematopoietic stem cells

A study led by scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key player contributing to the maintenance of hematopoietic stem cells (HSCs), blood cell precursors which have the ability to become any type of blood cell in the body.

17 Feb 2016

Current evidence insufficient to assess benefits and harms of screening for ASD

The U.S. Preventive Services Task Force has concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for autism spectrum disorder (ASD) in children 18 to 30 months of age for whom no concerns of ASD have been raised by their parents or a clinician.

17 Feb 2016

New study could help explain critical shortcomings in stem cell-driven therapies for heart disease

With every heart attack, billions of cardiomyocytes, the contracting heart muscle cells that make the heart pump time after time over a lifetime, are lost which can lead to heart failure or injury. Stem cell-based replacement strategies could open new and much needed therapeutic avenues.

17 Feb 2016

Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Researchers at UT Southwestern Medical Center have identified synthetic RNA and DNA that reverses the protein deficiency causing Friedreich's ataxia, a neurological disease for which there is currently no cure.

17 Feb 2016

Physical therapy reduces urinary problems in postmenopausal women with osteoporosis

After menopause, women with osteoporosis struggle more with urinary incontinence than women with healthy bones do. But physical therapy that includes pelvic floor muscle training can produce dramatic improvements, shows a study published online today in Menopause, the journal of The North American Menopause Society.

17 Feb 2016

CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma Corp. today reported financial results for the fourth quarter and full year ended December 31, 2015.

17 Feb 2016

CTCA hosts second ‘Annual New Treatments in Oncology’ conference

Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) is hosting its second Annual New Treatments in Oncology (ANTO) conference, focused on advances in cancer research, new treatments and patient care.

17 Feb 2016

MemorialCare partners with Fresenius Medical Care to operate 15 dialysis clinics in Southern California

MemorialCare Health System announced today that it has entered into a joint venture partnership with Fresenius Medical Care North America to operate 15 dialysis clinics in Orange and Los Angeles counties. Thirteen of these clinics are fully operational and two additional clinics are being developed in San Juan Capistrano and Huntington Beach.

17 Feb 2016

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it has received funding approval in the amount of €3 million from the German Federal Ministry of Education and Research for the so-called CancerMark project.

16 Feb 2016

IRIDEX's Cyclo G6 laser system receives CE Mark approval for treatment of glaucoma

IRIDEX Corporation, a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that it has received its CE Mark to commercialize across Europe its first laser system in its class designed solely for use in treating glaucoma and its symptoms.

16 Feb 2016

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival.

16 Feb 2016

Therapy News and Research

Chemotherapy better than chemoradiotherapy in reducing distant pancreatic cancer recurrences

Pioglitazone drug may prevent recurrent stroke and heart attacks

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

Allo-HSCT Non-Relapse Related Mortality Reduction Revealed

Mtss1 'tumour suppressor' for CML

Magnesium therapy as a relaxing Mother’s day gift

High beam placement accuracy from new Excelitas surface mount 905nm

Studies explore causative factor of hypertension in younger, obese men and women

Benefit of using antibody-coated drug-eluting stents for CHD still unclear, shows report

NUS-led study reveals key player contributing to maintenance of hematopoietic stem cells

Current evidence insufficient to assess benefits and harms of screening for ASD

New study could help explain critical shortcomings in stem cell-driven therapies for heart disease

Synthetic RNA and DNA could reverse protein deficiency that causes Friedreich's ataxia

Physical therapy reduces urinary problems in postmenopausal women with osteoporosis

CTI BioPharma announces Q4 and FY 2015 earnings

CTCA hosts second ‘Annual New Treatments in Oncology’ conference

MemorialCare partners with Fresenius Medical Care to operate 15 dialysis clinics in Southern California

Apogenix awarded €3 million grant to develop immuno-oncology candidate APG101 as personalized therapy

IRIDEX's Cyclo G6 laser system receives CE Mark approval for treatment of glaucoma

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News